Back to search
Charcot-Marie-Tooth Type 1A
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Charcot-Marie-Tooth Type 1A trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Charcot-Marie-Tooth Type 1A trials you may qualify forThe purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.
This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A usin…
The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F). MRI is an…
Charcot-Marie-Tooth disease type 1A is the most common form of inherited neuropathy that causes peripheral nerve damage in all four limbs. In addition to the we…
An Open, Dose-escalation, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of EN001 in Patients with Charcot-Marie-Tooth Disease type 1A (CMT1A)